Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 10:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,497 matching trials from the live ClinicalTrials.gov search.
Conditions
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions
HC-7366
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
Conditions
Nonsquamous Non-small Cell Lung Cancer
Interventions
Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Combination Product
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Glendale, Arizona • Norwich, Connecticut • Fredericksburg, Virginia
Conditions
Lung Cancer
Interventions
docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
Drug · Other · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM438, Pembrolizumab (KEYTRUDA ®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
38
States / cities
Beverly Hills, California • Fullerton, California • La Jolla, California + 33 more
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
doxorubicin hydrochloride
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
46
States / cities
Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 42 more
Conditions
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Interventions
Ruxolitinib, Retifanlimab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Conditions
Thyroid Nodule, Thyroid Cancer, Thyroid Diseases, Thymic Carcinoma
Interventions
Not listed
Lead sponsor
Aventura Hospital and Medical Center
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Conditions
Postoperative Pain, Breast Cancer
Interventions
Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels, 10 cc of 0.375% ropivacaine pectoral nerve block
Drug
Lead sponsor
Timothy R Petersen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Completed Phase 2 Interventional Results available

Sunitinib in Never-Smokers With Lung Adenocarcinoma

NCT01829217
Conditions
Lung Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Bio-Seal Biopsy Track Plug

NCT00527722
Conditions
Lung Cancer
Interventions
Bio-Seal Track Plug, No lung plug
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
Interventions
CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
mistletoe extract, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Interventions
YH42946
Drug
Lead sponsor
Yuhan Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
IORT-Intra-Operative Radiation Therapy
Interventions
Intraoperative Radiotherapy, Oncoplastic partial mastectomy
Radiation · Procedure
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota